| A year in our understanding of COVID-19 #MMPMID33125171Thwaites RSClin Exp Immunol 2020[Nov]; 202 (2): 146-148 PMID33125171show ga
ä|Antibodies, Monoclonal, Humanized/therapeutic use[MESH]|Betacoronavirus/*physiology[MESH]|Blood Coagulation[MESH]|COVID-19[MESH]|COVID-19 Vaccines[MESH]|Complement System Proteins/metabolism[MESH]|Coronavirus Infections/*immunology/prevention & control/therapy[MESH]|Humans[MESH]|Immunotherapy/*methods[MESH]|Interferon Type I/*immunology[MESH]|Pandemics/prevention & control[MESH]|Pneumonia, Viral/*immunology/prevention & control/therapy[MESH]|Receptors, Interleukin-6/immunology[MESH]|SARS-CoV-2[MESH]
DeepDyve Pubget Overpricing |
|